A good commentary: a single comparator product should be used for generic products not national references.
May 03, 2017
"...The selection of the comparator is a national responsibility and may be different between countries. This paper discusses the current recommendations on selection of comparators, the associated problems, and the possibility of harmonization. Most countries follow the World Health Organization (WHO) recommendations for selecting comparator products and require the comparator product to be obtained from their national markets to ensure switchability between the local comparator and their generics. These recommendations are only feasible in the few countries where the repetition of the bioequivalence study is economically feasible, but they are impracticable in all other countries ... the exclusive use of the local comparator to ensure switchability is ethically and scientifically questionable. The innovator product from well-regulated markets should be the global comparator. This harmonization is feasible as the concept already applies in the WHO prequalification program. It is ineffectual to harmonize only the requirements for performing bioequivalence studies, if such a study has to be repeated for every single country simply because of the different comparator products."
About Aedestra (www.aedestra.com): Aedestra is an inhaled product development company. We develop inhaled dosage form: DPI, pMDI, Nasal, Nebule and SoftMist: Generics in particular. Aedestra can help you develop the right product in the right way by providing strategic and technical expertise. Get in touch now to expand and develop your inhaled portfolio: www.aedestra.com.